J&J poised to take on Bostox, Reuters reports

Johnson & Johnson (JNJ) plans to take on Botox maker Allergan (AGN) and expects to seek U.S. approval next year for an anti-wrinkle drug that could break Botox's 85% market share, reports Reuters.

Advertisement